MedTrace Logo

EGO-COMBO Clinical End-point Extension Study Beyond 36 Months

NCT02263313 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 59

Last updated 2014-10-13

No results posted yet for this study

Summary

In this study, the safety and efficacy of COMBO TM stent beyond 36 months are assessed, in particular the occurrence of late stent thrombosis and late loss catch-up (restenosis).

Conditions

  • Coronary Restenosis

Interventions

OTHER

EGO-COMBO group

Assess the safety and effectiveness of Combo stent

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Wai Luen Stephen LEE, MD · The Univeristy of Hong Kong

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02263313 on ClinicalTrials.gov